Company

Abcellute was founded in September 2001 as a spinout from the School of Biosciences, Cardiff University. Abcellute’s core technology is based on a novel matrix which permits the preservation and storage of fresh primary liver cells or hepatocytes for up to 5 days at non-freezing temperatures without loss of biological function or principle biomarkers.

The company’s primary strategy is to attain global adoption of its cell preservation platform technology, thereby providing the research community with enhanced cell systems to improve management and development of key areas such as pre-clinical drug evaluation and regenerative medicine.

Abcellute operates out of several laboratory units, including Cardiff University and the Medicentre, Heath Hospital, Cardiff. Private equity and VC funded, the company has a highly experienced scientific (5 PhDs; 1 MSc), commercial and financial team.

“Hepatocytes stored on proprietary matrix showed consistent expression of P450 enzymes for up to 7 days, and consistent synthesis of testosterone metabolites for up to 4 days. These cells may represent a useful and convenient model for acute toxicity work.”